Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.77 |
| ▸ | RAF1 | P04049 | 10/20 | 0.77 |
| ▸ | EGFR | P00533 | 4/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5256236 | 0.91 | MAP2K1 (0.77) | MAP2K1RAF1EGFRERBB2MAPK13 | |
| SCHEMBL30301819 | 0.90 | MAP2K1 (0.62) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL17858745 | 0.90 | MAP2K1 (0.62) | MAP2K1RAF1EGFRERBB2SRC | |
| Hydrochloric Acid SCHEMBL17845966 | 0.89 | MAP2K1 (0.61) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL15320481 | 0.87 | MAP2K1 (0.77) | MAP2K1RAF1EGFRERBB2MAPK13 | |
| SCHEMBL4960679 | 0.86 | MAP2K1 (0.71) | MAP2K1RAF1EGFRERBB2SRC | |
| SCHEMBL27707570 | 0.86 | MAP2K1 (1.00) | MAP2K1RAF1ERBB2MAPK13SRC | |
| SCHEMBL5253113 | 0.85 | MAP2K1 (0.82) | MAP2K1RAF1EGFRERBB2MAPK13 | |
| SCHEMBL5254847 | 0.83 | MAP2K1 (0.73) | MAP2K1RAF1EGFRERBB2MAPK13 | |
| SCHEMBL4775969 | 0.82 | MAP2K1 (0.71) | MAP2K1RAF1EGFRERBB2MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101223143-A | 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same | WYETH CORP (US) | 2008-07-16 | — | — | CN | disclosed |
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | MAP2K1 818/4885RAF1 187/4885EGFR 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.